Bayer buys Perfuse in $2.4B deal for midphase eye disease prospect
The buyout, which includes up to $2.15 billion in milestones, will give Bayer control of an eye disease implant that Perfuse linked to improved outcomes in a pa...
The buyout, which includes up to $2.15 billion in milestones, will give Bayer control of an eye disease implant that Perfuse linked to improved outcomes in a pair of phase 2 trials last year.